Interestingly, PD-L1 expression has been reported to be downregulated by the EMT-repressor microRNA-200 (miR-200) in Non-Small-Cell Lung Carcinoma (NSCLC) [52,53] and breast carcinoma cells [54], hence unveiling a link between inhibitory immune checkpoint expression and the acquisition of a mesenchymal phenotype in cancer. The gene discussed is CD274; the disease is breast carcinoma.